Nasdaq
$2.94▼ 2.49%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $197.5MShares out 67.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.29Pre-market26.09.29 22:158-KKey event#●●●#●●●
Liminatus Pharma, Inc.Bullish
Liminatus Pharma has regained compliance with Nasdaq's minimum bid price rule following a 1-for-50 reverse stock split. Nasdaq confirmed that the company maintained a closing bid price above $1.00 for 13 consecutive trading days from August 21 to September 9, 2026, officially closing the delisting matter.…more
$2.94-2.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.18After-hours26.08.19 05:068-KKey event
Liminatus Pharma, Inc.
Liminatus Pharma is implementing a 1-for-50 reverse stock split after the market close on August 20, 2026, to satisfy Nasdaq continued listing requirements. This action will reduce the total outstanding shares from approximately 67.16 million to 1.34 million, with split-adjusted trading beginning on the Nasdaq Capital Market on August 21, 2026.…more
$2.94-2.49%vs prev closeView filingShare - 8.4After-hours26.08.05 05:308-KKey event
Liminatus Pharma, Inc.
Liminatus Pharma는 2026년 8월 3일 개최된 연례 주주총회에서 이사 선임 및 외부감사인 선임을 승인했습니다. 또한 나스닥 상장 유지 요건인 최소 입찰 가격을 충족하기 위해 최대 1대 50 비율의 역병합(주식 병합) 시행 권한을 이사회에 부여하는 안건을 가결했습니다.…more
$2.94-2.49%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.29Pre-market26.09.29 22:00#●●●
Liminatus Pharma Regains Nasdaq Compliance
Liminatus Pharma has regained compliance with Nasdaq's minimum bid price rule following a 1-for-50 reverse stock split. While this resolves the immediate delisting risk, it does not reflect improvements in the company's underlying business performance.…more
$2.94-2.49%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.24Pre-market26.08.24 21:00
●●●●●●●● ●●●●● ●●●●●●
Liminatus Pharma has partnered with CRO Synex to support the Phase 1/2a clinical trial of its CAR-T therapy candidate, IBC101, in South Korea. While this marks progress in clinical execution, the company remains in the early development stage with no guaranteed clinical outcomes.…more
$2.94-2.49%vs prev close - 8.24Pre-market26.08.24 21:01
●●●●●●●● ●●●●● ●●●●●●
Liminatus Pharma has engaged Korean CRO Synex to support the clinical development of its CD19xCD22 CAR-T therapy candidate, IBC101. This partnership aims to accelerate the Phase 1/2a clinical study for relapsed or refractory DLBCL patients in South Korea.…more
$2.94-2.49%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report